Imagen de portada del espectáculo EQUITY.GURU podcast - Investing for millennials and madmen

EQUITY.GURU podcast - Investing for millennials and madmen

Podcast de EQUITY.GURU

inglés

Negocios

Oferta limitada

2 meses por 1 €

Después 4,99 € / mesCancela cuando quieras.

  • 20 horas de audiolibros / mes
  • Podcasts exclusivos
  • Podcast gratuitos
Empezar

Acerca de EQUITY.GURU podcast - Investing for millennials and madmen

Equity.Guru's Chris Parry and his expert journalism team talk to business leaders, executives and investors about opportunities in North America and beyond.

Todos los episodios

120 episodios

Portada del episodio Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Highlights

Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Highlights

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Here are the highlights!

23 de nov de 2020 - 6 min
Portada del episodio Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 2

Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 2

Welcome to the second installment! Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Listen in!

23 de nov de 2020 - 20 min
Portada del episodio Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 1

Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 1

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Tune in!

23 de nov de 2020 - 0
Soy muy de podcasts. Mientras hago la cama, mientras recojo la casa, mientras trabajo… Y en Podimo encuentro podcast que me encantan. De emprendimiento, de salid, de humor… De lo que quiera! Estoy encantada 👍
Soy muy de podcasts. Mientras hago la cama, mientras recojo la casa, mientras trabajo… Y en Podimo encuentro podcast que me encantan. De emprendimiento, de salid, de humor… De lo que quiera! Estoy encantada 👍
MI TOC es feliz, que maravilla. Ordenador, limpio, sugerencias de categorías nuevas a explorar!!!
Me suscribi con los 14 días de prueba para escuchar el Podcast de Misterios Cotidianos, pero al final me quedo mas tiempo porque hacia tiempo que no me reía tanto. Tiene Podcast muy buenos y la aplicación funciona bien.
App ligera, eficiente, encuentras rápido tus podcast favoritos. Diseño sencillo y bonito. me gustó.
contenidos frescos e inteligentes
La App va francamente bien y el precio me parece muy justo para pagar a gente que nos da horas y horas de contenido. Espero poder seguir usándola asiduamente.

Elige tu suscripción

Más populares

Oferta limitada

Premium

20 horas de audiolibros

  • Podcasts exclusivos

  • Disfruta los podcast de Podimo sin anuncios

  • Cancela cuando quieras

2 meses por 1 €
Después 4,99 € / mes

Empezar

Premium Plus

100 horas de audiolibros

  • Podcasts exclusivos

  • Disfruta los podcast de Podimo sin anuncios

  • Cancela cuando quieras

Disfruta 30 días gratis
Después 9,99 € / mes

Prueba gratis

Sólo en Podimo

Audiolibros populares

Preguntas frecuentes

Más preguntas y respuestas
Empezar

2 meses por 1 €. Después 4,99 € / mes. Cancela cuando quieras.